Somatostatin receptor sst2A is highly expressed in fibrotic lung tissue in IPF patients. Uptake of a somatostatin analogue octreotide is elevated in the lungs of IPF patients.
Octreotide has been widely used for the treatment of neuroendocrine tumours.
A team of French scientists initiated a study that evaluated the safety and efficacy of intramuscular long-actingoctreotide as a therapy for IPF. This was an open-label, proof-of-concept, non-randomised, non-controlled, multicentre phase II study on 25 patients over 48 weeks performed in France between October 2006 and April 2008.
The study concluded that long-acting octreotide is well tolerated and provide a proof of concept that octreotide treatment slows down the progression of lung fibrosis. A larger placebo-controlled study is needed to confirm the efficacy.
Reference
Crestani B, et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J. 2012 Mar;39(3):772-5. PubMed PMID: 22379151.
Octreotide has been widely used for the treatment of neuroendocrine tumours.
A team of French scientists initiated a study that evaluated the safety and efficacy of intramuscular long-actingoctreotide as a therapy for IPF. This was an open-label, proof-of-concept, non-randomised, non-controlled, multicentre phase II study on 25 patients over 48 weeks performed in France between October 2006 and April 2008.
The study concluded that long-acting octreotide is well tolerated and provide a proof of concept that octreotide treatment slows down the progression of lung fibrosis. A larger placebo-controlled study is needed to confirm the efficacy.
Reference
Crestani B, et al. Octreotide treatment of idiopathic pulmonary fibrosis: a proof-of-concept study. Eur Respir J. 2012 Mar;39(3):772-5. PubMed PMID: 22379151.
No comments:
Post a Comment